Surufatinib Plus Cadonilimab in Patients With Unresectable or Metastatic Bile Duct Adenocarcinoma
This is an open-label, single-arm, multicenter Phase II clinical study to evaluate the efficacy and safety of surufatinib combined with cardanilimab in second-line treatment of patients with inoperable or metastatic bile duct adenocarcinoma
Bile Duct Adenocarcinoma
DRUG: surufatinib plus cadonilimab
Progression-free survival (PFS), Refers to the date from the date of admission to the date of the first progression of disease or death of any cause, using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)., up to 12 months
Overall survival (OS), The time interval between the start date of study drug and the date of death (any cause), up to 36 months|Objective response rate(ORR), The number of cases in which tumor size is reduced to PR or CR / the total number of evaluable cases (%), up to 12 months|Disease control rate (DCR), Percentage of confirmed cases including complete remission (CR), partial remission (PR) and disease stability (SD) among patients with evaluable efficacy, up to 12 months|Incidence of adverse events, Categorized according to NCI Common Toxicity Criteria version 5.0. Summarized in terms of type, severity (grade 1-5), and dose level in tabular format., Until the last medication for 30 days (Â±7 days) or before the start of other anti-tumor therapy (whichever occurs first)
This is an open-label, single-arm, multicenter Phase II clinical trial. It is planned to enroll patients with inoperable or metastatic bile duct adenocarcinoma who have progressed through first-line chemotherapy combined with immunotherapy in several hospitals across the country to evaluate the efficacy and safety of second-line treatment with surufatinib Combination With Cadonilimab.